A Trial Guided by Experts in the Field
To ensure that CONQUEST meets the highest standards of quality, the Scleroderma Research Foundation has assembled an expert team to guide and implement this innovative trial.
CONQUEST Steering Committee
Dinesh Khanna, MD, MSc, Co-Chair
University of Michigan School of Medicine
Toby Maher, MD, PhD, Co-Chair
Keck School of Medicine, University of Southern California
Yannick Allanore, MD, PhD
Hôpital Cochin
Shervin Assassi, MD, MS
McGovern Medical School, UTHealth Houston
Murray Baron, MD
Jewish General Hospital/McGill University
Elana Bernstein, MD
Columbia University
Vincent Cottin, MD, PhD
Louis Pradel University Hospital/Claude Bernard University
Francesco del Galdo, MD, PhD
University of Leeds
Christopher Denton, PhD
Royal Free Hospital/University College London
Jeska de Vries-Bouwstra, MD, PhD
Leiden University Medical Centre
Oliver Distler, MD
University Hospital Zurich
Tracy Frech, MD, MS
Vanderbilt Health
Jessica Gordon, MD
Hospital for Special Surgery
Kristin Highland, MD
Cleveland Clinic
Anna-Maria Hoffmann-Vold, MD, PhD
Oslo University Hospital
Laura Hummers, MD
Johns Hopkins Medicine
Yasuhiro Kondoh, MD, PhD
Tosei General Hospital
Masataka Kuwana, MD, PhD
Nippon Medical School
Marco Matucci-Cerinic, MD, PhD
Careggi University Hospital/University of Florence
Virginia Steen, MD
Georgetown University Medical Center
Luke Evnin, PhD, SRF representative non-voting member
Scleroderma Research Foundation
Greg Gordon, MD, JD, Non-voting member
Scleroderma Research Foundation, CONQUEST Study Team
More about CONQUEST.
About CONQUEST
CONQUEST is designed to rapidly advance promising treatments for scleroderma.
Patient Impact
CONQUEST offers unique benefits for scleroderma patients.
CONQUEST FAQ
Read our answers to our most frequently asked questions about CONQUEST.
ENROLLMENT INFORMATION
Join the quest to advance systemic sclerosis research through CONQUEST.
Consider enrolling in the CONQUEST study, a scleroderma clinical trial for people with systemic sclerosis-associated interstitial lung disease (SSc-ILD). Participants help progress research to potentially uncover new SSc-ILD treatment options.
Contact
If you are a healthcare provider or pharmaceutical company, please email info@conquestssc.org
If you are a person with scleroderma or a caregiver, please email info@sclerodermaresearch.org
